JMP Securities Transfers Coverage on Incyte (INCY), Upgrades to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Morgan Stanley Assumes Incyte (INCY) at Equalweight
September 5, 2019 3:37 AM EDTMorgan Stanley analyst Matthew Harrison assumes coverage on Incyte (NASDAQ: INCY) with a Equalweight rating and a price target of $87.00 (from $82.00).
For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.
Shares of Incyte closed at $77.62 yesterday.
... MoreOppenheimer Upgrades Incyte (INCY) to Outperform
September 5, 2019 3:28 AM EDTOppenheimer analyst Jay Olson upgraded Incyte (NASDAQ: INCY) from Perform to Outperform with a price target of $100.00.
The analyst comments "We upgrade INCY to Outperform based on attractive valuation for a company with increasing revenues, accelerating cash flows and a maturing... More
Incyte (INCY) Announces Data from its Oncology Portfolio to be Featured at ESMO
September 3, 2019 8:14 AM EDTIncyte (Nasdaq: INCY) announces that abstracts highlighting data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain from September 27-October 1, 2019.
Results from FIGHT-202, a Phase 2 study of pemigatinib as a second-line treatment for patients with advanced/metastatic or surgically unresectable cholangiocarcinoma, including updated safety and efficacy data in patients with FGFR2 fusions or rearrangements, as well as genomic profiling and correlations with clinical outcomes will be presented. Results from the Phase 1... More
